Drug Trial Radar · NCT06566820
Continuation Protocol for Obstructive Sleep Apnea (OSA)
Last checked: Nov 19, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
1,280
Planned (sponsor's estimate)
Start
Jul 3, 2024
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- ApnimedIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA). The present study is a Phase 3 open label continuation protocol enrolling qualifying participants who completed one of the parent Phase 3 double-blind placebo-controlled studies, APC-APN-304 or APC-APN-305.
Conditions
- OSA
Interventions
Aroxybutynin and AtomoxetineDrug
Fixed Dose Combination
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AES) and Serious Adverse Events (SAEs)Time frame: through study completion, an average of 1 year
- Number of Participants With Vital Signs AbnormalitiesTime frame: through study completion, an average of 1 year
- Number of Participants With Concomitant Therapy (Medication or Devices)Time frame: through study completion, an average of 1 year
Locations
99 sites in 2 countries. Site status is shown where the registry gives one.
Sleep Disorders Center of America
Birmingham, Alabama
The University of Alabama/Institute for Rural Health Research
Tuscaloosa, Alabama
Chandler Clinical Trials
Chandler, Arizona
Desert Clinical Reserach, LLC/CCT Research
Mesa, Arizona
Foothills Research Center/CCT Research
Phoenix, Arizona
Fiel Family and Sports Medicine/CCT Research
Tempe, Arizona
Noble Clinical Research
Tucson, Arizona
Preferred Research Partners, Inc.
Little Rock, Arkansas
Orange County Research Institute
Anaheim, California
Core Healthcare Group
Cerritos, California
Exalt Clinical Research, Inc.
Chula Vista, California
Collaborative Neuroscience Research, LLC
Los Alamitos, California
Santa Monica Clinical Trials
Los Angeles, California
Empire Clinical Research
Pomona, California
Probe Clinical Research Corporation
Riverside, California
Pacific Research Network
San Diego, California
TriValley Sleep Center
San Ramon, California
SDS Clinical Trials, Inc.
Santa Ana, California
Providere Research Inc.
West Covina, California
Mountain View Clinical Research, Inc.
Denver, Colorado
Meris Clinical Research
Brandon, Florida
Teradan Clinical Trials
Brandon, Florida
St. Francis Medical Institute
Clearwater, Florida
Nouvelle Clinical Research
Cutler Bay, Florida
Arrow Clinical Trials
Daytona Beach, Florida
Canvas Clinical Research
Lake Worth, Florida
Florida Lung & Sleep Associates
Lehigh Acres, Florida
Ivetmar Medical Group, LLC
Miami, Florida
Advanced Medical Research Institute
Miami, Florida
PharmaDev Clinical Research Institute, LLC
Miami, Florida
Flourish Research
Miami, Florida
Renstar Medical Research
Ocala, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
JSV Clinical Research Study Inc.
Tampa, Florida
Palm Beach Research Center
West Palm Beach, Florida
Central Florida Pediatric Sleep Disorders d/b/a Florida Pediatric Institute, LLC
Winter Park, Florida
Clinical Site Partners, LLC dba Flourish Research
Winter Park, Florida
Neurotrials Research Inc
Atlanta, Georgia
Atlanta Center for Medical Research
Atlanta, Georgia
CenExel iResearch, LLC
Decatur, Georgia
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.